Page 355 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 355
LP14 A PHASE 3, RANDOMISED, OPEN-LABEL STUDY TO LATE BREAKER ePOSTERS
EVALUATE THE EFFICACY AND SAFETY OF 12 AND 8
LP15 WEEKS OF SIMEPREVIR (SMV) PLUS SOFOSBUVIR (SOF)
LP16 IN TREATMENT-NAÏVE AND -EXPERIENCED PATIENTS
LP17 WITH CHRONIC HCV GENOTYPE 1 INFECTION WITHOUT
CIRRHOSIS: OPTIMIST-1
LP18 Paul Kwo*, Norman Gitlin, Ronald Nahass, David Bernstein,
Sergio Rojter, Eugene Schiff, Mitchell Davis, Peter J. Ruane, Ziad Younes,
Ronald Kalmeijer, Monika Peeters, Oliver Lenz, Bart Fevery,
Guy De La Rosa, Jane Scott, Rekha Sinha, James Witek, The United States
SEPARATE AND COMBINED EFFECTS OF OBETICHOLIC
ACID AND WEIGHT LOSS IN NONALCOHOLIC
STEATOHEPATITIS (NASH)
Bilal Hameed*, Norah Terrault, Ryan Gill, Rohit Loomba,
Naga Chalasani, Jay H. Hoofnagle, Mark L. Van Natta, The United States
MUTATIONS IN DCDC2, ENCODING DOUBLECORTIN
DOMAIN-CONTAINING PROTEIN 2, CAUSE NEONATAL
SCLEROSING CHOLANGITIS
Tassos Grammatikopoulos*, Sandra Strautnieks, Melissa Sambrotta,
A. S. Knisely, Giorgina Mieli-Vergani, Joshua Smith, Laura Bull,
Richard J. Thompson, The United Kingdom
NOVEL APPROACH FOR THE PREVENTION OF
RECURRENT HEPATITIS C IN LIVER TRANSPLANT
RECIPIENTS: PRELIMINARY RESULTS FROM ONGOING
PHASE III TRIAL WITH CIVACIR®
Norah Terrault*, Roshan Shrestha, Sanjaya K. Satapathy,
Jacqueline G. O’Leary, Jeffrey Campsen, Jens Rosenau, James Spivey,
Lewis W. Teperman, George Therapondos, Elizabeth C. Verna,
John M. Vierling, Thomas D. Schiano, Linda Sher, Hicham Khallafi,
David Victor, Kalyan R. Bhamidimarri, Fredrick D. Gordon,
Steven Hanish, Laura M. Kulik, Gerond Lake-Bakaar, Daniel Maluf,
Michael Porayko, Steven L. Bramer, Greg Osgood, Shailesh Chavan,
Nicole Daelken, The United States
OBETICHOLIC ACID FOR NASH: BENEFITS IN A HIGH RISK
SUBGROUP AND THE EFFECTS OF CONCOMITANT STATIN
USE
Brent Neuschwander-Tetri, Arun Sanyal*, Rohit Loomba,
Naga Chalasani, Kris Kowdley, Manal Abdelmalek, Elizabeth Brunt,
David Shapiro, The United States
Vienna, Austria • April 22–26, 2015 355
EVALUATE THE EFFICACY AND SAFETY OF 12 AND 8
LP15 WEEKS OF SIMEPREVIR (SMV) PLUS SOFOSBUVIR (SOF)
LP16 IN TREATMENT-NAÏVE AND -EXPERIENCED PATIENTS
LP17 WITH CHRONIC HCV GENOTYPE 1 INFECTION WITHOUT
CIRRHOSIS: OPTIMIST-1
LP18 Paul Kwo*, Norman Gitlin, Ronald Nahass, David Bernstein,
Sergio Rojter, Eugene Schiff, Mitchell Davis, Peter J. Ruane, Ziad Younes,
Ronald Kalmeijer, Monika Peeters, Oliver Lenz, Bart Fevery,
Guy De La Rosa, Jane Scott, Rekha Sinha, James Witek, The United States
SEPARATE AND COMBINED EFFECTS OF OBETICHOLIC
ACID AND WEIGHT LOSS IN NONALCOHOLIC
STEATOHEPATITIS (NASH)
Bilal Hameed*, Norah Terrault, Ryan Gill, Rohit Loomba,
Naga Chalasani, Jay H. Hoofnagle, Mark L. Van Natta, The United States
MUTATIONS IN DCDC2, ENCODING DOUBLECORTIN
DOMAIN-CONTAINING PROTEIN 2, CAUSE NEONATAL
SCLEROSING CHOLANGITIS
Tassos Grammatikopoulos*, Sandra Strautnieks, Melissa Sambrotta,
A. S. Knisely, Giorgina Mieli-Vergani, Joshua Smith, Laura Bull,
Richard J. Thompson, The United Kingdom
NOVEL APPROACH FOR THE PREVENTION OF
RECURRENT HEPATITIS C IN LIVER TRANSPLANT
RECIPIENTS: PRELIMINARY RESULTS FROM ONGOING
PHASE III TRIAL WITH CIVACIR®
Norah Terrault*, Roshan Shrestha, Sanjaya K. Satapathy,
Jacqueline G. O’Leary, Jeffrey Campsen, Jens Rosenau, James Spivey,
Lewis W. Teperman, George Therapondos, Elizabeth C. Verna,
John M. Vierling, Thomas D. Schiano, Linda Sher, Hicham Khallafi,
David Victor, Kalyan R. Bhamidimarri, Fredrick D. Gordon,
Steven Hanish, Laura M. Kulik, Gerond Lake-Bakaar, Daniel Maluf,
Michael Porayko, Steven L. Bramer, Greg Osgood, Shailesh Chavan,
Nicole Daelken, The United States
OBETICHOLIC ACID FOR NASH: BENEFITS IN A HIGH RISK
SUBGROUP AND THE EFFECTS OF CONCOMITANT STATIN
USE
Brent Neuschwander-Tetri, Arun Sanyal*, Rohit Loomba,
Naga Chalasani, Kris Kowdley, Manal Abdelmalek, Elizabeth Brunt,
David Shapiro, The United States
Vienna, Austria • April 22–26, 2015 355
